---
title: "Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284802061.md"
description: "Shandong Weigao Group Medical Polymer Co has established a Korea-focused private fund through its subsidiary, Wego Healthcare Fund, targeting small and mid-sized enterprises specializing in open innovation and cross-border expansion. The fund is set at KRW52.97 billion, with Wego Healthcare committing KRW15.89 billion. This transaction is classified as connected under Hong Kong listing rules, requiring reporting but not independent shareholder approval. The latest analyst rating for Shandong Weigao stock is a Hold with a price target of HK$4.00."
datetime: "2026-04-30T15:29:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284802061.md)
  - [en](https://longbridge.com/en/news/284802061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284802061.md)
---

# Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) just unveiled an update.

Shandong Weigao Group Medical Polymer has moved to deepen its investment footprint by setting up a Korea-focused private fund through its indirect wholly owned unit, Wego Healthcare Fund. The vehicle will target small and mid-sized enterprises in Korea and abroad that specialise in open innovation and cross-border expansion involving companies, universities and research institutions.

The fund is planned at KRW52.97 billion, with Wego Healthcare Fund committing KRW15.89 billion, or 30% of total capital, alongside general partners including Wego (HK) and SV Investment. The transaction is classified as a connected one under Hong Kong listing rules, triggering reporting and announcement requirements but not independent shareholder approval, underscoring the group’s use of affiliated structures to pursue overseas growth while staying within compliance thresholds.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

**More about Shandong Weigao Group Medical Polymer Co**

Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical products manufacturer listed in Hong Kong. The group operates through subsidiaries including Wego Healthcare Fund and Wego (HK), and focuses on healthcare-related investments and operations across Greater China and overseas markets.

**Average Trading Volume:** 21,134,478

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$16.05B

For an in-depth examination of 1066 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01066.HK](https://longbridge.com/en/quote/01066.HK.md)

## Related News & Research

- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [Hong Kong’s MPF authority flags fraudulent certificates in early pension payouts](https://longbridge.com/en/news/286657515.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Slovenia’s SMEs battle labour shortages and rising costs as enterprise fund pushes green and digital shift](https://longbridge.com/en/news/286675840.md)
- [UAE among first globally to approve new obesity, hypertension treatments](https://longbridge.com/en/news/286707352.md)